1) Byrd, JC. Ibrutinib versus Ofatumumab in Previously Treated Chronic
Lymphoid Leukemia. NEJM. 2014. Available from: http://www.nejm.org/
[http://www.nejm.org ]. Accessed May 2014.
2) U.S. Food and Drug Administration. Press Announcement: FDA approves Imbruvica
for rare blood cancer. Nov 2013. Available from:
http://www.fda.gov/newsevents/newsroom/p.... Accessed
May 2014.
3) U.S. Food and Drug Administration. Press Announcement: FDA approves Imbruvica
to treat chronic lymphocytic leukemia. Feb 2014. Available from:
http://www.fda.gov/newsevents/newsroom/p.... Accessed
May 2014.
4) American Cancer Society. "Leukemia--Chronic Lymphocytic". Available from:
http://www.cancer.org/acs/groups/cid/doc.... Accessed
April 2014.
5) Parker, T. Chronic lymphocytic leukemia: prognostic factors and impact on
treatment. Discovery Medicine. 2011; 57.
6) Veliz M, Pinilla-Ibarz J. Treatment of relapsed or refractory chronic
lymphocytic leukemia. Cancer Control. 2012 Jan;19(1):37-53.
7) Qiu Y, Kung HJ. Signaling network of the Btk family kinases. Oncogene
2000;19:5651-61.
8) Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of
B-cell differentiation. Nat Rev Immunol. 2002;2:920-32.
9) Puri KD, di Paolo JA, Gold MR. B-cell receptor signaling inhibitors for
treatment of autoimmune inflammatory diseases and B-cell malignancies. Int Rev Immunol
2013;32:397-427.
10) Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a
therapeutic target in CLL. Blood 2012;120:1175-84.
11) Akinleye A, Chen Y, Mukhi N, Song Y, Liu D. Ibrutinib and novel BTK
inhibitors in clinical development. J Hematol Oncol 2013;6:59.
Media Inquiries:
Satu Kaarina Glawe
Mobile: +49(172)294-6264
Investor Relations:
Stan Panasewicz
Phone: +1-732-524-2524
Louise Mehrotra
Phone: +1-732-524-6491
